An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Tipifarnib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms THoMAS
Most Recent Events
- 28 Mar 2024 Status changed from active, no longer recruiting to discontinued,as the recruitment was closed prematurely to due to slow recruitment.
- 29 Mar 2023 Planned End Date changed from 30 Oct 2023 to 30 Jul 2023.
- 21 Sep 2022 Status changed from recruiting to active, no longer recruiting.